Zofran and Atrophic vulvovaginitis - a phase IV clinical study of FDA data

Summary:

Atrophic vulvovaginitis is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are 50-59 old, also take Aredia, and have Breast cancer.

The phase IV clinical study analyzes which people have Atrophic vulvovaginitis when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Atrophic vulvovaginitis?

Atrophic vulvovaginitis (inflammation of the vulva) is found to be associated with 300 drugs and 296 conditions by eHealthMe. Check the latest studies of Atrophic vulvovaginitis.

On Jul, 12, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 20 people (0.02%) have Atrophic vulvovaginitis.

Could Zofran cause Atrophic vulvovaginitis?

Among these 20 people:

What is the age of people who have Atrophic vulvovaginitis when taking Zofran? *

What are other drugs people take besides Zofran? *

What are other side effects people have besides Atrophic vulvovaginitis? *

Stress And Anxiety: 18 people, 90.00%
Joint Pain: 15 people, 75.00%
Anaemia (lack of blood): 15 people, 75.00%
Pain: 15 people, 75.00%
Indigestion: 13 people, 65.00%
Fatigue (feeling of tiredness): 13 people, 65.00%
Depression: 12 people, 60.00%
Neuropathy Peripheral (surface nerve damage): 12 people, 60.00%
Emotional Distress: 12 people, 60.00%
Urinary Tract Infection: 11 people, 55.00%

What are the existing conditions these people have? *

Breast Cancer: 8 people, 40.00%
Ovarian Cancer (cancer of ovary): 4 people, 20.00%
Metastases To Bone (cancer spreads to bone): 3 people, 15.00%
Pain: 2 people, 10.00%
Vomiting In Pregnancy: 1 person, 5.00%
Multiple Myeloma (cancer of the plasma cells): 1 person, 5.00%
Morning Sickness (sickness in morning during pregnancy): 1 person, 5.00%
Migraine (headache): 1 person, 5.00%
Light Chain Analysis Increased: 1 person, 5.00%
Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Atrophic vulvovaginitis?

- Check whether Atrophic vulvovaginitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Zofran (94,987 reports)

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Atrophic vulvovaginitis:

Atrophic vulvovaginitis (300 drugs)

Browse all the conditions that are associated with Atrophic vulvovaginitis:

Atrophic vulvovaginitis (296 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.